Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICCMNASDAQ:NTRBNASDAQ:VANINASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICCMIceCure Medical$1.01-0.5%$1.05$0.48▼$1.66$56.06M0.33479,192 shs208,123 shsNTRBNutriband$7.98+1.9%$6.56$3.72▼$11.78$89.01M1.1180,908 shs58,223 shsVANIVivani Medical$1.32+0.8%$1.12$0.91▼$1.50$78.20M2.93100,680 shs124,810 shsXAIRBeyond Air$0.16-2.0%$0.20$0.15▼$0.68$13.82M0.231.55 million shs2.85 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICCMIceCure Medical0.00%+6.18%-1.94%-9.01%+35.70%NTRBNutriband0.00%+2.44%+23.53%+27.48%+47.78%VANIVivani Medical0.00%+4.76%+10.00%+18.92%+3.13%XAIRBeyond Air0.00%-30.97%-15.79%-41.20%-74.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICCMIceCure Medical2.6287 of 5 stars3.84.00.00.02.00.00.6NTRBNutriband3.3412 of 5 stars3.55.00.00.02.61.70.6VANIVivani Medical3.3395 of 5 stars3.55.00.00.02.23.30.0XAIRBeyond Air4.2828 of 5 stars3.73.00.03.52.50.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICCMIceCure Medical 3.50Strong Buy$2.50147.52% UpsideNTRBNutriband 3.00Buy$13.0062.91% UpsideVANIVivani Medical 3.00Buy$4.00203.03% UpsideXAIRBeyond Air 3.33Buy$1.50837.50% UpsideCurrent Analyst Ratings BreakdownLatest XAIR, ICCM, VANI, and NTRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.505/19/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/16/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/4/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICCMIceCure Medical$3.29M17.04N/AN/A$0.12 per share8.42NTRBNutriband$2.14M41.58N/AN/A$0.46 per share17.35VANIVivani MedicalN/AN/AN/AN/A$0.30 per shareN/AXAIRBeyond Air$3.70M3.73N/AN/A$0.75 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICCMIceCure Medical-$15.32M-$0.28N/AN/AN/A-467.37%-182.26%-112.65%8/19/2025 (Estimated)NTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/2/2025 (Estimated)VANIVivani Medical-$23.49M-$0.43N/AN/AN/AN/A-133.07%-56.50%8/12/2025 (Estimated)XAIRBeyond Air-$46.62M-$0.79N/AN/AN/A-1,258.46%-233.96%-113.92%8/5/2025 (Estimated)Latest XAIR, ICCM, VANI, and NTRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025XAIRBeyond Air-$0.14-$0.09+$0.05-$0.09$1.39 million$1.15 million5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 million5/28/2025Q1 2025ICCMIceCure Medical-$0.08-$0.06+$0.02-$0.06$0.75 million$0.73 million5/13/2025Q1 2025VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A4/28/2025Q4 2025NTRBNutriband-$0.12-$0.18-$0.06-$0.51$0.71 million$0.64 million3/31/2025Q4 2024VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICCMIceCure MedicalN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICCMIceCure Medical0.021.891.48NTRBNutriband0.013.713.48VANIVivani MedicalN/A2.402.40XAIRBeyond Air0.643.203.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICCMIceCure Medical0.62%NTRBNutriband19.70%VANIVivani Medical6.78%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipICCMIceCure Medical2.44%NTRBNutriband54.09%VANIVivani Medical46.40%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICCMIceCure Medical6055.50 million54.15 millionNot OptionableNTRBNutriband1011.15 million5.12 millionNot OptionableVANIVivani Medical2059.24 million31.76 millionOptionableXAIRBeyond Air7086.37 million69.61 millionOptionableXAIR, ICCM, VANI, and NTRB HeadlinesRecent News About These CompaniesBeyond Air Inc.June 26 at 2:50 PM | barrons.comHere's Why Beyond Air (XAIR) Could be Great Choice for a Bottom FisherJune 26 at 10:56 AM | zacks.comBeyond Air (XAIR) Q4 2025 Earnings Call TranscriptJune 21, 2025 | msn.comFY2029 EPS Estimates for Beyond Air Lifted by Roth CapitalJune 21, 2025 | americanbankingnews.comBeyond Air, Inc. (NASDAQ:XAIR) Q4 2025 Earnings Call TranscriptJune 20, 2025 | msn.comBeyond Air posts narrower-than-feared Q4 loss, shares surge 15%June 18, 2025 | investing.comBeyond Air Reports Strong Revenue Growth and Strategic AdvancesJune 17, 2025 | tipranks.comBeyond Air, Inc. (XAIR) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | finance.yahoo.comBeyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue EstimatesJune 17, 2025 | zacks.comBeyond Air Stock Dips After Mixed Q4 Results: Here's What To KnowJune 17, 2025 | benzinga.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | globenewswire.comBeyond Air Submits PMA Supplement Application for Next-Generation LungFit PH II Nitric Oxide GeneratorJune 16, 2025 | quiverquant.comQBeyond Air Submits FDA PMA Supplement for Next Generation LungFit® PHJune 16, 2025 | globenewswire.comBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3, 2025 | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAIR, ICCM, VANI, and NTRB Company DescriptionsIceCure Medical NASDAQ:ICCM$1.01 -0.01 (-0.49%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.03 +0.02 (+1.58%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Nutriband NASDAQ:NTRB$7.98 +0.15 (+1.92%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$8.02 +0.04 (+0.51%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Vivani Medical NASDAQ:VANI$1.32 +0.01 (+0.76%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.24 -0.08 (-6.14%) As of 06/27/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Beyond Air NASDAQ:XAIR$0.16 0.00 (-2.02%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.16 0.00 (-0.63%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
